Patient
SITE003-0222
enrolled Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE003 (CAN) (Dr. Okafor)
consented 2026-05-23
Adverse events
2
Serious AEs
1
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 2
mild
assessed
2026-07-19
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-01-12 (study day 45); relationship: not assessed
severe
serious
assessed
2026-06-19
Grade 4 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-12-13 (study day 15); relationship: not assessed; serious criteria: life-threatening
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.